Single‐center outbreak of Pneumocystis jirovecii pneumonia in heart transplant recipients. Issue 3 (25th March 2018)

• Record Type: Journal Article
• Authors: Veronese, Giacomo; Ammirati, Enrico; Moioli, Maria Cristina; Baldan, Rossella; Orcese, Carlo Andrea; De Rezende, Gisele; Veronese, Silvio; Masciocco, Gabriella; Perna, Enrico; Travi, Giovanna; Puoti, Massimo; Cipriani, Manlio; Tiberi, Simon; Cirillo, Daniela; Frigerio, Maria
• Is Part Of: Transplant infectious disease. Volume 20:Issue 3(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2018-03-25
• Subjects: epidemiology -- genotyping -- heart transplantation -- outbreak -- Pneumocystis jirovecii; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12880
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Background: Pneumocystis jirovecii pneumonia (PJP) outbreaks are described in solid organ transplant recipients. Few reports suggest interhuman transmission with important infection control implications. We described a large PJP outbreak in heart transplant (HTx) recipients. Methods: Six cases of PJP occurred in HTx recipients within 10 months in our hospital. Demographics, clinical characteristics, treatment and outcomes were described. To identify contacts among individuals a review of all dates of out‐patient visits and patient hospitalizations was performed. Cross exposure was also investigated using genotyping on PJ isolates. Results: At the time of PJP‐related hospitalization, patients' mean age was 49 ± standard deviation 4 years, median time from HTx was 8 (25%‐75% interquartile range [Q1‐Q3] 5‐12) months and none of the cases were on prophylaxis. At PJP‐related admission, 5 patients had CMV reactivation, of whom 4 were on antiviral preemptive treatment. Median in‐hospital stay was 30 (Q1‐Q3, 28‐48) days; and 2 cases required intensive care unit admission. All patients survived beyond 2 years. Transmission map analysis suggested interhuman transmission in all cases (presumed incubation period, median 90 [Q1‐Q3, 64‐91] days). Genotyping was performed in 4 cases, demonstrating the same PJ strain in 3 cases. Conclusions: We described a large PJP cluster among HTx recipients, supporting the nosocomial acquisition of PJP through interhuman transmission. Based on this experience, extended prophylaxis for more than 6 months after HTx could be considered in specific settings. Further work is required to understand its optimal duration and timing based on individual risk factor profiles and to define standardized countermeasures to prevent and limit PJP outbreaks.